SF1126 for Patients With Relapsed or Refractory Neuroblastoma
Status:
Terminated
Trial end date:
2018-05-22
Target enrollment:
Participant gender:
Summary
SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting
of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin
expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will
follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified,
an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or
Myc expression will be treated.
Funding Source - FDA OOPD
Phase:
Phase 1
Details
Lead Sponsor:
New Approaches to Neuroblastoma Therapy Consortium
Collaborators:
SignalRX Pharmaceuticals, Inc. University of Southern California